Iron and Chronic Obstructive Pulmonary Disease (COPD) Exercise Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-01

Study Completion Date

2019-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II single centre, double blind, placebo-controlled, randomised trial aims to test the hypothesis that intravenous iron improves exercise performance in Chronic Obstructive Pulmonary Disease (COPD) as measured by constant rate cycle ergometry.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Validation of the 1-minute Sit-to-stand Test in Patients With COPD

NCT02441725

Pulmonary Disease, Chronic Obstructive

COMPLETED NA

Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients

NCT02416778

Pulmonary Disease, Chronic Obstructive

UNKNOWN PHASE4

Balance Training in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01424098

Chronic Obstructive Pulmonary Disease

COMPLETED NA

Home-based Exercise Training for COPD Patients

NCT03461887

Chronic Disease Lung Diseases, Obstructive Respiratory Disease

COMPLETED NA

Comparing Measurements Made in an Incremental Shuttle Walk Test and a Cardiopulmonary Exercise Test in Patients With IPF

NCT03360032

Idiopathic Pulmonary Fibrosis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Iron deficiency (ID) is one of the most common nutritional deficiencies affecting humans. Chronic diseases, including COPD, are commonly complicated by iron deficiency anaemia (IDA). It has been well documented that there is an association between both ID and anaemia and reduced exercise capacity. It has been postulated that addressing this ID may be a novel approach to improve exercise capacity and quality of life.

The ECLIPSE cohort found that the prevalence of anaemia in patients with COPD is 19% and is associated with functional limitation and poor outcomes; similarly Nickol et al (2015) found ID to be prevalent in 17.7% of patients with COPD.

Barberan-Garcia et al (2015) evaluated the relationship between Non-anaemic iron deficiency (NAID) and aerobic capacity in seventy COPD patients before and after an 8 week high intensity endurance exercise training programme. Endurance time was assessed as endurance time during constant work rate exercise testing at 80% of oxygen consumption (VO2) peak. At baseline it was noted that the NAID group in comparison to the normal iron status group had a lower exercise tolerance of approximately 90 seconds, which is close to normally reported minimal clinical important difference (MCID's) for this test, P=0.007. After adjusting for confounding variables with a multiple regression analysis it was shown that training induced increase in aerobic exercise capacity was only found in the normal iron status group, with the effect of training on exercise tolerance being lower in the NAID (P=0.041).

Exercise capacity in COPD is strongly linked to outcome measures and mortality. The benefit of correcting NAID in COPD subjects would be to achieve an increase in exercise endurance and thus an improvement in Quality of Life (QoL). Currently there is no standard treatment for NAID in COPD, so this pilot, randomised, double-blind, placebo-controlled trial will attempt to answer this question.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Double blind, placebo-controlled, randomised trial

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active

Ferric Carboxymaltose (FCM) (Ferinject) at 15 mg iron/kg body weight

Group Type EXPERIMENTAL

Ferric Carboxymaltose

Intervention Type DRUG

Ferric Carboxymaltose injectable Product

Placebo

Sodium Chloride 0.9%

Group Type PLACEBO_COMPARATOR

Sodium Chloride 0.9%

Intervention Type DRUG

Sodium Chloride 0.9%

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ferric Carboxymaltose

Ferric Carboxymaltose injectable Product

Intervention Type DRUG

Sodium Chloride 0.9%

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ferinject®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Clinically stable patients (\>18 years old), Global Initiative for Chronic Obstructive Lung Disease (GOLD) II-IV COPD Forced Expiratory Volume in 1 second (FEV1):Forced Vital capacity (FVC) \< 0.70
2. Non-anaemic: males haemoglobin (Hb) ≥ 130g/L, and females ≥ 120g/L
3. Iron deficiency, defined as:

1. Serum Ferritin \< 100 µg/ml
2. Serum Ferritin 100-299 µg/ml with Transferrin saturation (TSAT) \< 16%
3. Soluble transferring receptor \> 28.1nmol/L
4. No history of lower respiratory tract infection or exacerbation of COPD in the last 6 weeks
5. No participation in Pulmonary Rehabilitation (PR) for at least 3 months prior to initial assessment.

Exclusion Criteria

1. Polycythemia defined as Hb \> 170g/L and haematocrit \> 0.6 in males and Hb \> 150g/L and haematocrit \> 0.56 in females.
2. Significant co-morbidity contributing to reduced exercise tolerance
3. Congestive cardiac failure defined as Left Ventricular Ejection Fraction (LVEF) \< 45% or plasma B-type natriuretic peptide (BNP) \> 100pg/ml.
4. Oral iron therapy at doses \> 100mg/day in the previous week prior to randomisation.
5. Chronic liver disease (including active hepatitis) and/or screening alanine transaminase or aspartate transaminase above 3 times the upper limit of normal range.
6. Anaemia (WHO \[31\]) defined as Hb \< 130g/L in males \> 15 yrs old and Hb \< 120g/L in non-pregnant females.
7. Current malignancy or haematological disorders.
8. Currently receiving systemic chemotherapy and/or radiotherapy.
9. Renal dialysis (previous, current or planned).
10. Unstable angina.
11. Subject is of child-bearing potential or is pregnant or breast feeding.
12. Contraindication to Ferrous Carboxymaltose (Ferinject):

1. Hypersensitivity to active substance
2. Known serious hypersensitivity to other parental iron substance
3. Anaemia not attributed to iron deficiency (e.g. other microcytic anaemia)
4. Evidence of iron overload or disturbance in utilisation of iron.

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No